Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Cardiotoxicity 1

Interventions

Doxorubicin 15 Exercise 9 Cyclophosphamide 9 Dexrazoxane 8 Razoxane 6 Carvedilol 6 Vincristine 4 Trastuzumab 4 Radiotherapy 4 Filgrastim 4 Docetaxel 4 Methotrexate 3 Granulocyte Colony-Stimulating Factor 3 Etoposide 3 Echocardiography 3 Atorvastatin 3 salicylhydroxamic acid 2 sacubitril and valsartan sodium hydrate drug combination 2 empagliflozin 2 dapagliflozin 2 Tablets 2 Silymarin 2 Prednisone 2 Paclitaxel 2 Neoadjuvant Therapy 2 Leucovorin 2 Ivabradine 2 High-Intensity Interval Training 2 Epirubicin 2 Electrocardiography 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Cardiotoxicity × schizandrin × Clear all

NCT06214195 2024-01-19

START

Zhejiang Cancer Hospital

Phase 3 Recruiting

Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon ⚡